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Abstract
 
Allogeneic stem cell transplantation (SCT) can induce curative graft-versus-tumor reactions in
patients with hematological malignancies and solid tumors. The graft-versus-tumor reaction af-
ter human histocompatibility leukocyte antigen (HLA)-identical SCT is mediated by alloimmune
donor T cells specific for polymorphic minor histocompatibility antigens (mHags). Among
these, the mHag HA-1 was found to be restricted to the hematopoietic system. Here, we re-
port on the HA-1 ribonucleic acid expression by microdissected carcinoma tissues and by sin-
gle disseminated tumor cells isolated from patients with various epithelial tumors. The HA-1
peptide is molecularly defined, as it forms an immunogenic peptide ligand with HLA-A2 on
the cell membrane of carcinoma cell lines. HA-1–specific cytotoxic T cells lyse epithelial tu-
mor cell lines in vitro, whereas normal epithelial cells are not recognized. Thus, HA-1–specific
immunotherapy combined with HLA-identical allogeneic SCT may now be feasible for pa-
tients with HA-1
 
  
 
carcinomas.
Key words: stem cell transplantation • graft-versus-tumor • carcinomas • cytotoxic T cells • 
minimal residual disease
 
Introduction
 
Overall mortality from solid cancers has only slightly de-
creased despite earlier diagnosis, improved surgical tech-
niques, and novel therapy regimens (1). One of the prom-
ising novel therapies is the application of stem cell
transplantation (SCT).
 
* 
 
Clinical and experimental data in-
dicate that allogeneic SCT not only reconstitutes the pa-
tient’s hematopoietic system, but also mediates a powerful
curative effect in patients transplanted for hematological
malignancies or solid tumors (2–8). These alloimmune
graft-versus-host reactions generally lack tumor specificity
and are often accompanied by severe GVHD. Therefore,
definition of novel target structures for systemic therapy of
carcinomas is needed. The prerequisites of target antigens
for successful immunotherapy of cancers are tissue specific-
ity, functional membrane expression on the tumor cells,
and the capacity of inducing alloimmune T cell responses.
The graft-versus-host reactions after HLA-identical SCT
are attributed by antigens encoded by genes other than the
MHC, which are generally referred to as minor histocom-
patibility antigens (mHags; reference 9). mHags are pep-
tides from polymorphic intracellular proteins that are en-
coded by genes on the Y chromosome and autosomal
genes. Their immunogenicity arises as a result of their ex-
pression on the plasma membrane where they are recog-
nized by alloreactive MHC-restricted T cells (10). We
demonstrated earlier that mHags either show ubiquitous or
restricted tissue expression (11). The tissue expression of
the mHag HA-1 is limited to the hematopoietic cells.
Functional studies with HA-1–specific CTLs demonstrated
the efficient lysis of hematopoietic cells, including leukemic
cells (11, 12) and the inhibition of leukemic progenitor cell
outgrowth (13), whereas no CTL recognition was ob-
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served when nonhematopoietic cells were used as target
cells (11). The mHag HA-1, with its tissue distribution
restricted to hematopoietic cells, fulfills the prerequisites
for successful immunotherapy of hematological tumors.
Therefore, we developed ex vivo protocols to treat leuke-
mia relapse after HLA-matched mHag HA-1–mismatched
SCT with low risk of GVHD. Here, donor-derived CTLs
specific for the hematopoietic system–specific mHag HA-1
are generated (14)
 
.
 
 Upon transfusion, these SCT donor–
derived HA-1–specific CTLs will eliminate the HA-1
 
  
 
pa-
tients’ hematopoietic and leukemic cells, while HA-1
 
 
 
nonhematopoietic cells and normal tissues will be spared.
Here, we report that HA-1, in addition to its exclusive
expression on the hematopoietic cell lineage, is aberrantly
expressed on epithelial tumor cells with no expression on
normal epithelial cells. Our observation of HA-1 expres-
sion on various types of nonhematological tumors offers a
novel target molecule for the treatment of epithelial tu-
mors. Similar to the immunotherapy protocol for the treat-
ment of relapsed leukemia as described above, the aberrant
expression of HA-1 on carcinoma cells may be exploited
for the treatment of HA-1
 
  
 
carcinoma patients in combina-
tion with HLA-identical HA-1
 
  
 
SCT.
 
Materials and Methods
 
mRNA Levels by Quantitative Real-time PCR.
 
Total RNA was
prepared from subconfluent layers of the adherent cell cul-
tures using the RNAzol method (Cinaa/Biotecx Laboratories,
Inc.) according to the manufacturer’s instructions. cDNA was
synthesized using 2 
 
 
 
g RNA and random hexameric primers.
PCR amplification and quantification were performed using the
Taqman PCR assay (7700 Sequence Detector; Applied Biosys-
tems). We used comparative quantification that normalized the
HA-1 and CD45 gene to an internal standard gene, the ubiqui-
tously expressed housekeeping gene 
 
porphobilinogen deaminase
 
(PBGD). The relative levels of expression of the HA-1 and
CD45 genes in the test samples were calculated as percentages of
the levels of expression in the reference cell line KG-1, which
expresses both genes. All samples that showed expression levels
 
 
 
10% in the real-time quantitative PCR did not produce de-
tectable PCR fragments in a standard PCR. Therefore, expres-
sion levels 
 
 
 
10% are considered not significant. The relative
quantification calculated by the linear calibration function be-
tween the threshold cycle (C
 
t
 
) value and the logarithm of the
initial starting quantity (N) were C
 
t 
 
   
 
3.31 log (N) 
 
  
 
26.1, C
 
t 
 
 
 
 
3.5 log (N) 
 
  
 
21.6, and C
 
t 
 
   
 
3.41 log (N) 
 
  
 
25.6 for HA-1,
CD45, and PBGD, respectively. The HA-1, CD45, and PBGD
expression were quantified in all test samples using these calibra-
tion functions.
 
Preparation of Cryosections.
 
5-
 
 
 
m sections from freshly snap
frozen primary tumors were placed on a polyethylene membrane
on a glass slide, stained with Meyer’s hematoxylin, and dehy-
drated in 70%, 90%, and 100% ethanol. The PALM Microbeam
system (Bernried) was used for microdissection and catapulting.
The PALM laser microdissection microscope was provided by
Altana Pharma.
 
HA-1 and CD45 Expression Analysis on Primary and Single Dis-
seminated Epithelial Cancer Cells.
 
The detection of disseminated
cells and the global amplification of microdissected areas and of
single cells from bone marrow and lymph nodes were performed
 
as previously described (15). For the detection of HA-1 and CD-
45 message by gene-specific PCR, we used 1 
 
 
 
l of the primary
product after global PCR. For the highest sensitivity, 50 cycles
for all primer pairs were run. All samples were analyzed by two
primer pairs for HA-1: (I) forward 5
 
 
 
-GAC GTC GTC GAG
GAC ATC TCC CAT-3
 
  
 
and
 
 
 
reverse 5
 
 
 
-GAA GGC CAC AGC
AAT CGT CTC CAG-3
 
  
 
and (II) forward 5
 
 
 
-ACA CTG CTG
TCG TGT GAA GTC-3
 
  
 
and
 
 
 
reverse 5
 
 
 
-TCA GGC CCT GCT
GTA CTG CA-3
 
 
 
, and by one primer pair for CD45: forward
5
 
 
 
-CTG AAG GAG ACC ATT GGT GA and reverse 5
 
 
 
-GGT
ACT GGT ACA CAG TTC GA-3
 
  
 
primer. Amplification prod-
ucts of the HA-1 (I) primers were digested with the restriction
enzyme BstUI and amplification products of the HA-1 (II) prim-
ers with HinfI. Southern blot was performed according to stan-
dard protocols.
 
CTL Recognition Studies.
 
Tumor cell lines were used as target
cells in a standard 4-hr 
 
51
 
Cr release assay. The tumor cells from
subconfluent cultures were harvested and dispensed at 2,500
cells/well in 96-well flat-bottomed microtiter plates and allowed
to attach either in the presence or absence of 250 U/ml rIFN
 
 
 
and 250 U/ml TNF
 
  
 
(both from Genentech, Inc.) for 48 h. The
tumor cells were labeled with 
 
51
 
Cr for 1hr. The experiments
were performed in sixplicates. The percentage-specific lysis was
calculated as follows: % specific lysis 
 
  
 
(experimental release 
 
 
 
spontaneous release) / (maximal release 
 
  
 
spontaneous release) 
 
  
 
100.
 
Primary Cultures and Cell Lines Used.
 
The following primary
cell cultures were provided: proximal tubular epithelial cells by
M. Daha, melanocytes by N. Schmitt, Langerhans cells by M.
Mommaas, and keratinocytes and fibroblasts by Mrs. J.
Kempenaar (all from Leiden University Medical Center, Leiden,
Netherlands). The following cell lines were provided: MDA-MB
231, 734 B, MCF-7, and ZR75-1 by B. Eibl (University Hospital
of Internal Medicine, Innsbruck, Austria); HBL-100 cell line,
Mel 93.04, LB 33, MZ 1851, MZ 1752, and MZ 1774 by S.
Osanto (Leiden University Medical Center, Leiden, Nether-
lands); SW 707, SW 2219, SW620, Col 205, and SW 948 by
H.W. Verspaget (Leiden University Medical Center, Leiden,
Netherlands); BT-20, BT, MEWO, E9, BT, MNT, and BA by
G.C. de Gast (University Medical Center, Utrecht, Netherlands);
GLC2, GLC 8, and GLC 36 by L. de Leij (Academisch Zieken-
huis Groningen, Groningen, Netherlands); BB74/2940, KUL
68/3636, and BB 49/1413 by F. Brasseur (Ludwig Institute for
Cancer Research, Brussels, Belgium); HuH7 and HepG2 by B.J.
Scholte (Erasmus University, Rotterdam, Netherlands); and SW
480 by G. Eisner (University Regensburg, Regensburg, Ger-
many). Mast cell lines and HT29 (American Type Culture Col-
lection [ATCC]: HTB-37) and Caco-2 (ATCC: HTB-37),
which are ATCC cell lines, were provided by B. Henz (Charité-
Virchow Klinikum, Berlin, Germany).
 
Results
 
HA-1 Transcription Is Restricted to Cells of the Hematopoietic
Lineage.
 
Earlier, functional studies with mHag HA-1–
specific CTL clones demonstrated the hematopoietic re-
stricted tissue distribution of the mHag HA-1 (11). To
confirm the latter restricted tissue distribution on the tran-
scriptional level, HA-1 mRNA levels were analyzed by
quantitative real-time PCR in eight different hematopoi-
etic and six different nonhematopoietic cell types. Only cells
of hematopoietic origin expressed significant levels of the 
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HA-1 gene (Fig. 1). No significant HA-1 gene expression
was detected in cells of nonhematopoietic origin, i.e., kera-
tinocytes, dermal fibroblasts, proximal tubular epithelial
cells, umbilical vein endothelial cells, melanocytes, and
normal breast cell lines HaCaT and HBL 100 (Fig. 1).
CD45 mRNA expression was analyzed in parallel. The
transcription levels of HA-1 and CD45 were very similar
with significant levels of expression in hematopoietic cells
and insignificant levels (i.e., 
 
 
 
10%) in nonhematopoietic
cells (unpublished data).
 
HA-1 Transcription in Tumor Cell Lines.
 
The HA-1 gene
transcription levels were analyzed in 35 nonhematopoi-
etic epithelial tumor cell lines derived from different types
of carcinomas (Table I). The HA-1 gene transcription,
analyzed by quantitative real-time RT-PCR, revealed
significant HA-1 mRNA in 26 out of the 35 cell lines
of various nonhematopoietic malignant origins. HA-1
mRNA has also been recently demonstrated on 17 tumor
cell lines of nonhematopoietic origin by Fujii et al. (16). To
justify the HA-1 expression on the cell lines, we executed
the CD45 gene expression in parallel. None of the tumor
cell lines we analyzed showed significant CD45 gene ex-
pression, demonstrating that HA-1 transcription observed
in the tumor cell lines is not due to contaminating hemato-
poietic cells (Table I).
 
HA-1–specific Lysis of Tumor Cell Lines.
 
Functional rec-
ognition by HA-1–specific CTLs is a prerequisite for tu-
mor-specific targeting in immunotherapeutical settings.
The mHag HA-1 locus encodes two alleles, the HA-1
 
H 
 
and
the HA-1
 
R 
 
allele. The HA-1
 
H 
 
allele is the T cell epitope
that is recognized by HLA-A2–restricted HA-1–specific
Figure 1. HA-1 gene expression is restricted to hematopoietic cells.
The relative HA-1 gene expression levels were determined in cells of he-
matopoietic and nonhematopoietic origin. Hematopoietic cells tested
were: *, PBMCs (n   3);  , dendritic cells (n   6);  , Langerhans cells
(n   2);  , EBV-LCLs (n   5);  , PHA blasts (n   6);  , mast cell lines
(n   3);  , monocytes (n   4); and  , thymocytes (n   3). Nonhemato-
poietic cells tested were:  , keratinocytes (n   5);  , fibroblasts (n   2);
 , proximal tubular epithelial cells (PTECs; n   3);  , umbilical vein
endothelial cells (HUVECs; n   3);  , melanocytes (n   3); and two
SV40 immortalized breast cell lines:  , HaCat and  , HBL-100.
 
Table I.
 
HA-1 Gene Expression in Tumor Cell Lines
 
Tumor type Cell line HA-1 percentage
 
a
 
Breast cancer ZR75-1 54
BT-20 40
734B 27
T47 D 17
MDA-MB231 15
MCF-7
 
 
 
10
BT 474
 
 
 
10
Melanoma Mel 93.04 68
KUL 68/3636 67
BB 74/2940 57
MNT 27
LB33 24
BT 15
453 Ao 12
518A
 
 
 
10
E9
 
 
 
10
MEWO
 
 
 
10
Lung carcinoma GLC 36 22
GLC 8
 
 
 
10
GLC 2
 
 
 
10
Renal cell carcinoma MZ 1851 29
MZ 1752 13
MZ 1774
 
 
 
10
BA
 
 
 
10
Hepatoma HuH7 37
HepG2 35
Colon carcinoma SW 707 147
CaCo-2 81
SW 480 70
SW 2219 48
SW 620 28
Col 205 21
SW 948 12
HT29 11
Head and neck cancer BB 49/1413 54
 
a
 
The percentage of CD45 gene expression was 
 
 10 for all of the sam-
ples tested.362 Aberrant Expression of the mHag HA-1 in Carcinomas
CTLs (17). The exclusive specificity of the CTLs for the
HLA-A2/HA-1H ligand has been extensively demonstrated
earlier in immunogenetic and segregation analyses and on
the molecular level (17–19). Thus, the conditions for CTL
recognition studies are the expression of both the HLA-A2
restriction molecule and the HA-1H T cell epitope on the
tumor cell lines. Here, all the tumor cell lines (Table I)
with significant HA-1 gene expression levels, but no CD45
RNA levels, were HLA and HA-1 genotyped (20). Those
cell lines positive for both the HLA-A2 and HA-1H alleles
were selected for functional CTL analyses. Table II shows
significant lysis of the five HLA-A2/HA-1H  cell lines by
two HA-1–specific clones that could be enhanced in all
cases by IFN  and TNF  treatment of the target cells. The
colon carcinoma cell line CaCo-2 was recognized by one
of the two HA-1–specific CTL clones and only upon
Table II. HA-1–specific Lysis of Nonhematopoietic Tumor Cell Lines
Percent-specific lysis by
allo HLA-A2 CTLs
Percent-specific lysis by
HLA-A2/HA-1 CTLs
1E2
IFN /TNF 
5W38
IFN /TNF 
3HA15
IFN /TNF 
Tumor type Target cell designation E/T ratio no yes no yes no yes
A2 HA-1H
Breast cancer MDA-MB231 2:1 10 13 8 15 8 13
10:1 50 64 31 47 25 39
Melanoma MEL 93.04 2:1 10 14 1 13  21 0
10:1 54 64 12 37 17 40
Melanoma 453 AO 2:1 7 24 1 10 1 18
10:1 25 43 5 21 2 22
20:1 35 45 7 24 7 21
Lung carcinoma GLC 36 1:1 33 35 6 12 0 8
10:1 59 80 8 25 17 25
Colon carcinoma CaCo-2 1.6:1 20 22 1 2 6 7
16:1 29 49 4 4 11 17
A2 HA-1R
Breast cancer 734B 2:1 29 41 3 1 4 0
10:1 32 67 5 1 0 0
Melanoma MNT 1:1 33 51 0 0 1 1
10:1 62 84 3 3 0 0
Melanoma BT 1:1 33 36 0 0 0 4
10:1 76 79 0 0 0 9
A2-ve
Breast cancer ZR75-1 1:1 0 0 0 0 0 0
10:1 0 2 1 6 0 0
Controls
EBV-LCLs A2 HA-1H 1:1 60 ND 35 ND 24 ND
10:1 87 ND 43 ND 43 ND
A2 HA-1H 1:1 69 ND 51 ND 32 ND
10:1 83 ND 41 ND 68 ND
A2 HA-1R 1:1 54 ND 6 ND 4 ND
10:1 81 ND 3 ND 0 ND
A2 HA-1R 1:1 55 ND 0 ND 1 ND
10:1 83 ND 1 ND 0 ND
The percentage of specific lysis by one allo HLA-A2 and two HLA-A2/HA-1 CTLs was determined with at least two effector to target cell (E:T) ratios.
The lysis of HLA-A2/HA-1H tumor cell lines by the allo HLA-A2 and HLA-A2/HA-1 CTLs, and the lysis on HLA-A2  and HA-1R tumor cell lines by
allo HLA-A2 CTLs, but not by the HLA-A2/HA-1 CTLs, is shown. The absence of lysis on an HLA-A2  tumor cell line by the allo HLA-A2 CTLs and
the HLA-A2/HA-1 CTLs is also shown. The control target cells used in the same experiments, HLA-A2/HA-1H–typed EBV-LCLs, are lysed by the allo
HLA-A2 and HLA-A2/HA-1 CTLs. HLA-A2  and HA-1R–typed EBV-LCLs are lysed by the allo HLA-A2 CTLs, but not by the HLA-A2/HA-1 CTLs.363 Klein et al.
IFN  and/or TNF  treatment of the cell line. All carci-
noma cell lines were also recognized by the allo HLA-A2
CTLs. The various control target cells are analyzed in par-
allel to the same experiments (Table II). The results show
the specificity of the HLA-A2/HA-1H CTLs, i.e., they
only show lysis on target cells expressing both the HLA-A2
molecule and the HA-1H peptide. These data are in agree-
ment with the exclusive HLA-A2/HA-1H specificity of
these CTLs as previously demonstrated (11–14, 17–20).
HA-1 Transcripts in Primary Epithelial Tumors. Next, we
aimed at analyzing the HA-1 expression by epithelial tu-
mors in vivo. However, given the expression of HA-1 by
hematopoietic cells and in view of the virtual omnipres-
ence of hematopoietic cells in tumors, positive results of a
PCR analysis caused by contaminating hematopoietic cells
should be avoided. To this end, we applied laser-mediated
microdissection to cryosections of fresh frozen cancer sam-
ples (Fig. 2 A). This enables the isolation of a selected area
by a laser beam and directly catapults it into the reaction
tube. Hence, contamination by surrounding tissue is practi-
cally excluded. However, infiltration of the tissues by a sin-
gle or a few hematopoietic cells, or contamination by invis-
ible mRNA molecules that result from the generation of
the cryosections, cannot entirely be ruled out. Therefore,
various controls were performed. First, the CD45 gene-
specific PCR was run in parallel to all tumor samples to test
whether HA-1 expression might be attributed to single in-
filtrating leukocytes or intravascular cells. The absence of
CD45 mRNA will provide strong evidence that the HA-1
signal originates from the epithelial tumor cells in vivo,
whereas the coamplification of HA-1 and CD45 of micro-
dissected areas would not provide evidence of the HA-1
expression by tumor cells. Second, the sensitivity and reli-
ability of the amplification protocol was tested using pri-
mary lymph nodes. Tiny areas from 5,000 to 40,000  m2
were microdissected and the isolated mRNA was globally
amplified (15). From the primary product, 1 out of 50 was
used in the secondary PCRs for the housekeeping gene
EF-1 , HA-1, and CD45 (Fig. 2 B). Although all samples
were positive for EF-1 , HA-1 and CD45 could only be
detected in areas larger than 5,000  m2, indicating the de-
tection limit of the approach for these samples. As ex-
pected, HA-1 and CD45 were strictly coexpressed in the
positive samples, demonstrating similar expression levels in
these lymph nodes. Third, we investigated normal breast
tissues for the presence of both HA-1 and CD45 messages.
We microdissected areas from 10,000 to 40,000  m2 of
normal breast glands from three patients who underwent
breast reduction surgery. From eight out of nine areas,
mRNA was successfully isolated as judged by the amplifi-
cation of EF-1 . Except for one area (NB-3.1), which was
positive for HA-1, all samples were negative for both HA-1
and CD45 messages. The results on lymph nodes and nor-
mal breast tissues indicate that the applied approach reliably
detected infiltrating lymphocytes via the coexpression of
HA-1 and CD45, whereby the latter always appears more
Figure 2. HA-1 and CD45 ex-
pression of microdissected tissue
samples. (A) Laser microdissection of
a normal breast gland, from which
mRNA was subsequently isolated.
The cryosection with the clearly vis-
ible glandular structure is shown on
the left. On the right, the mammary
cells have been microdissected and
catapulted into the reaction tube us-
ing a laser beam. (B) Gene-specific
PCR of microdissected lymph nodes
(LN), normal breast (NB), and tu-
mor patients (PN) for EF-1 , HA-1,
and CD45 using amplicons after glo-
bal amplification of the cDNA that
was obtained from the microdissected
areas. Areas from 5,000 to 60,000
 m2 were individually analyzed. M,
size marker;  , HT29 for HA-1 and
normal bone marrow for CD45;  ,
water control.364 Aberrant Expression of the mHag HA-1 in Carcinomas
intense. This further underlines our decision that only in
the absence of CD45 mRNA, a positive judgment on the
HA-1 expression, is allowed. The results on the normal tis-
sues also demonstrate that contamination by invisible nu-
cleic acids from the process of tissue preparation would
very rarely lead to spurious results.
Next, we investigated primary cancers. From the tumors
of seven patients with breast and lung cancers, we isolated
27 areas from 10,000 to 60,000  m2 comprising  30–200
cells. Except for one area (PN-17.1), mRNA could be suc-
cessfully isolated from all samples. 21 samples displayed
PCR bands of HA-1, whose identity was confirmed by
Southern blotting (unpublished data). 11 of the 26 samples
contained hematopoietic cell infiltrates as demonstrated by
the CD45 PCR band. Consequently, HA-1 expression of
these tumors could not be assessed. Of the 15 remaining
samples, 5 were negative for both CD45 and HA-1 (33%).
In one sample (PN-21.5), CD45 amplification in the ab-
sence of HA-1 was observed. However, in the remaining
nine samples (60%) that could be evaluated, HA-1 expres-
sion without CD45 expression was detected, providing
strong evidence that HA-1 is indeed expressed by primary
tumor cells. To test whether the lack of CD45 was just due
to spurious amplification of its message, we analyzed six
samples by array analysis. The labeled cDNAs were hybrid-
ized to a small array consisting of informative histogenetic
marker molecules (Fig. 3 A). Three of the six hybridized
samples (PN-18.3, PN-21.1, and PN-22.3) had been posi-
tive for HA-1 and negative for CD45 by gene-specific
PCR. The other three samples of PN-5 were positive for
both the HA-1 and CD45 genes (Fig. 2 B). On the array,
all six samples displayed signals for genes consistent with
their malignant epithelial origin, such as the epithelial-
restricted cytokeratins or the tumor-specific MAGE genes
(Fig. 3 A). Strikingly, although the CD45  samples coex-
pressed several other hematopoietic markers, such as
CD16, CD33, CD34, CD37, and CD38, no hybridization
signals for any of these genes was seen in the three samples
that were solely positive for HA-1. To finally prove that
the DNA of the microdissected areas that was hybridized
was isolated from tumor tissue, we performed comparative
genomic hybridization (CGH) on five of the six samples
from which genomic DNA had simultaneously been iso-
lated. The aberrant karyotypes showed that the areas were
isolated from tumor tissue (Fig. 3 B).
HA-1 Transcripts in Single Disseminated Tumor Cells.
Because of the strong evidence of HA-1 expression by
primary tumors, we analyzed the HA-1 expression on dis-
seminated tumor cells. Single disseminated cancer cells or
defined cell clusters were prepared from bone marrow and
lymph node samples using a fluorescent-labeled mono-
clonal antibody against the epithelial cell adhesion mole-
cule as marker (15). In total, 27 single tumor cells or small
cell clusters from 15 cancer patients were isolated by mi-
cromanipulation (Fig. 4 A). For cDNA analysis, the same
global amplification technique was applied that was used
for the microdissected tumor areas, enabling faithful de-
tection of expressed transcripts in viable single cells (15).
The labeled cDNAs were hybridized to an array including
specific epithelial marker genes, such as the cytokeratin
family members mammaglobin and prolactin-induced
protein as markers for breast-derived cells, and the tran-
scription factor ELF3. Additional evidence of epithelial
origin was provided by claudin 7 and desmoplakin I,
which are both involved in epithelial cell adhesion. Ex-
pression of cytokeratins and other epithelial markers indi-
cated their epithelial origin (Fig. 4 B). As an indicator of
malignancy, the MAGE genes were analyzed. In addition,
we evaluated the cells for markers of hematopoietic cells
such as the T cell receptor, CD45, CD33, CD34, CD37,
CD38, and CD16. None of the isolated cells expressed
one of the latter hematopoietic markers. All cells were
then tested for HA-1 and CD45 expression by gene-spe-
cific PCR. The HA-1 amplification products were subse-
quently confirmed by restriction enzyme digest and
Southern blotting. 6 of the 27 single disseminated cells
(22%) expressed the HA-1 gene, whereas none of them
expressed the CD45 gene (Fig. 5 A). The HA-1–signifi-
Figure 3. Validation of HA-1 expression in human
primary tumors. (A) Evaluation of histogenetic markers
by cDNA array analysis. Six microdissected areas that
were HA-1  by PCR were hybridized on a small array
containing histogenetic markers. PN5-1, PN5-2, and
PN5-3 were positive for CD45 in gene-specific PCR,
whereas PN18-3, PN21-1, and PN22-3 were CD45 .
Cytokeratin or MAGE transcripts represent epithelial
or tumor-specific transcripts, whereas CD markers in-
dicate leukocytic origin. ACTB and UB are house-
keeping genes and GFP is the negative control. The
gray shades represent the signal intensity, from light
gray (weak signal) to black (strong signal). (B) CGH re-
sults of five of the six areas
shown in A. The chromosome
arms are given with green indi-
cating a chromosomal gain and
red indicating a chromosomal
loss. The aberrations prove that
the isolated areas contained at
least 50% tumor cells.365 Klein et al.
cant transcripts were observed in samples derived from
bronchial carcinoma (PN3-C1, PN5-C4, and PN6-C5),
breast cancer (PN4-C1), cervical cancer (PN1-C1), and
prostate cancer (PN2-C1). From two of the HA-1  cells
(PN5-C4 and PN3-C1) we also evaluated their genomic
DNA by a recently described method (21). The isolated
DNA was subjected to whole genome amplification and
CGH. Both cells harbored multiple genomic alterations,
confirming their malignant nature as exemplified for
PN3-C1 in Fig. 5 B.
Discussion
We show HA-1 RNA transcription in tumor cell lines
of a wide array of epithelial neoplastic cells: breast, melano-
mas, lung, renal cell and colon carcinomas, hepatocellular
Figure 4. Isolation and HA-1
expression analysis of single dis-
seminated cancer cells or small
tumor cell clusters. (A) Three-
cell cluster (PN5-C4) after mi-
cromanipulator-assisted isolation
from a cell suspension of a lymph
node preparation. All cells of the
cluster are intensively stained by
the epithelial cell adhesion mole-
cule antibody. (B) Gene expres-
sion profiling on cDNA array of
isolated tumor cells. HA-1 ex-
pression after standard RT-PCR
is given in the first line. The gray
shades represent the signal inten-
sity, from light gray (weak signal)
to black (strong signal).366 Aberrant Expression of the mHag HA-1 in Carcinomas
carcinomas, and head and neck cancers. The cell lines that
express the HLA-A2 and HA-1 phenotypes, which are re-
quired for CTL recognition, were lysed by the HLA-A2–
restricted HA-1–specific CTL. We show that HA-1 is ex-
pressed by primary solid tumors and single disseminated
lung, breast, cervical, and prostatic carcinoma cells. Dis-
seminated cells from 6 out of 15 patients were positive for
HA-1. The fact that we could not detect the HA-1 mRNA
in all cells from one individual patient either indicates the
detection limit of our approach, or reflects tumor cell het-
erogeneity. Both reasons are equally plausible. In a separate
study, using the same amplification method, we noticed
that the detection of EMMPRIN mRNA in 60% of single
disseminated tumor cells corresponded to 80% expression
on the protein level (15). This suggests that HA-1 protein
expression might be more frequent than observed in this
study. In addition, HA-1 might also be heterogeneously
expressed on disseminated tumor cells. Interestingly, we re-
cently observed that genetic instability is the highest before
the diagnosis of overt metastasis (unpublished data). As
most cells analyzed here were isolated from bone marrow
or lymph nodes of patients in the clinical stage without
overt metastasis, it is very likely that the heterogeneous ex-
pression of HA-1 directly reflects the genetic instability at
Figure 5. HA-1 expression of
disseminated cancer cells. (A)
Cells positive for the HA-1 (II)
primer pair were digested with
HinfI, blotted, and hybridized
with the respective probe. M,
size marker; A, undigested PCR
product; B, HinfI-digested prod-
uct; lane 1, PN12-C1; lane 2,
PN4-C1; lane 3, PN3-C1; lane
4, PN5-C4; lane 5, PN6-C5;
lane 6, PN2-C1;  , HT29 for
HA-1 and normal bone marrow
for CD45. (B) CGH profile of
cell PN3-C1. Each chromosome
is represented by its ideogram
and numbered. Deletions are
marked with a red bar (e.g., loss
of chromosome 13) to the left
and gains are marked with a
green bar (e.g., gain of chromo-
some 8q) to the right of the
chromosome symbol.367 Klein et al.
the stage of minimal residual disease. The finding of HA-1
expression in the latter patients is of particular clinical im-
portance as this cell population includes the progenitor cells
of metachronic metastasis. Therefore, the investigation of
whether a more homogeneous HA-1 expression is associ-
ated with the progression to overt metastasis is relevant.
The mechanism of the aberrant HA-1 expression in epi-
thelial tumor cells is currently unknown. A variety of gene
families such as the MAGE or BAGE family give rise to tu-
mor-specific antigens (22, 23). These genes are both acti-
vated in tumors of different histological types and silent in
normal cells except for testicular germ cells. DNA methyla-
tion has been proposed as the primary mechanism for the
inactivation of genes (24). But DNA demethylation is not
always sufficient for the activation of genes in nonexpress-
ing cells (25, 26) and therefore the regulation by transcrip-
tion factors is also required (27). The function of the HA-1
gene, its promoter region, and the relevant transcription
factors involved in its activation are presently unknown.
Based on computer alignment, a RhoGAP domain was de-
fined within the HA-1–predictive protein (these sequence
data are available from Genbank/EMBL/DDBJ under ac-
cession no. XM 037574). Therefore, HA-1 might be a
GTPase activator protein for Rho-like GTPases. Members
of the Rho family are key regulators of the assembly and
organization of the actin cytoskeleton. Through their inter-
action with multiple target proteins, they ensure the con-
trol of cellular activities such as gene transcription and ad-
hesion (28). The determination of HA-1 target proteins,
functional studies, and analysis of its regulation will reveal
the role of HA-1 in cellular mechanisms and might explain
the aberrant expression in epithelial tumor cells.
The mHag HA-1 fulfills the prerequisites as target mole-
cule for successful immunotherapy of hematological tu-
mors. Here, we show that HA-1 can also function as a
novel target molecule for immunotherapy of carcinomas in
combination with HLA-matched HA-1–mismatched allo-
geneic SCT. In the HLA-identical allogeneic SCT setting
for solid tumors, graft-versus-tumor reactivity has been
suggested in small cohorts of patients with metastatic can-
cers, including breast cancer (5, 6, 29), melanomas (7), re-
nal cell carcinomas (4), and ovarian carcinoma (8). One
could speculate that this graft-versus-tumor reactivity may
be due to specific tumor-associated antigens, tissue- or cell-
specific polymorphic mHags such as HA-1. The relevance
of the HA-1–specific lysis in vitro on the tumor cell lines
restricts itself to the extent that the cell lines reflect tumor
cells as they exist in vivo. Yet, at a relatively low effector to
target ratio, the lysis can be interpreted as significant.
Nonetheless, the HA-1–specific lysis vary among the tu-
mor cell lines and is clearly lower compared with the lysis
of the EBV-lymphocyte cell lines (LCLs) in the absence of
IFN  and TNF . Evidently, in vivo recognition of tumor
cells is crucial. Inappropriate tumor cell lysis would hamper
the potential immunotherapy. It is of interest to note that
IFN  and TNF  treatment of the tumor cell lines enhances
the cytotoxic activity. It is known that these cytokines do
up-regulate MHC expression. This might be particularly
effective for ligands such as HLA-A2/HA-1 that have low
( 80) HA-1 peptide HLA-A2 complexes expressed per
cell (unpublished data). Similar to the immunotherapy pro-
tocol for the treatment of relapsed leukemia (14) as de-
scribed above, adoptive immunotherapy with donor-
derived HA-1 CTLs in combination with SCT can also
become an attractive treatment of solid tumors. As in the
leukemia transplant patients in which residual leukemic tu-
mor cells are present after high dose chemotherapy, HA-1–
based immunotherapy might be particularly warranted in
cancer patients with minimal residual disease who were
shown to confer an increased risk for a later occurring re-
lapse (30). The HA-1–based immunotherapy is as yet lim-
ited to HLA-A2  patients and the HA-1–incompatible
SCT patient and/or donor pairs. The HA-1H phenotype
frequency is 69% in the HLA-A2  population (17). Among
the HLA-identical HLA-A2  patient and/or donor sibling
pairs, there is 13% HA-1H incompatibility. It will be possi-
ble to extend the postulated therapy to HLA-B60  patients.
We recently observed an HLA-B60–restricted functional
HA-1 T cell epitope within the HA-1 polymorphic locus
(unpublished data). Evidently, the HA-1 expression among
tumor cells is heterogeneous, which further limits the pro-
posed immunotherapy. Nonetheless, the latter therapy
could represent an important proof of principle if it showed
that adoptive CTL immunotherapy targeted to specific
peptides with restricted tissue expression could be effective.
Future studies will also focus on peptide vaccination strate-
gies of stem cell donor and/or recipient in the HLA-
matched mHag HA-1–mismatched situation (31). In
conclusion, here we describe a constitutive human hemato-
poietic–specific gene that can function as a tumor-specific
antigen for epithelial cancer. The significance of the poly-
morphic mHag HA-1 for cancer therapy is underscored by
its absence of expression on nonmalignant epithelial cells,
its known HA-1–immunogenic functional membrane ex-
pression, and its adequate CTL recognition.
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